Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis

Annals of Pharmacotherapy

Volumn 30, Issue 7-8, 1996, Pages 752-755

  Yarboro, Cheryl H ^a   Wesley, Robert ^a   Amantea, Michael A ^b   Klippel, John H ^a   Pucino, Frank ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Sea Quest Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; LORAZEPAM; ONDANSETRON; THIETHYLPERAZINE;

ADULT; ANTIEMETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; SELF REPORT; VOMITING;

EID: 0030015937     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000708     Document Type: Article

References (15)

1. Boumpas DT, Austin HA III, Vaughan EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
2. Lehman TJA, Sherry DD, Wagner-Weiner L, McCurdy DK, Emery HM, Magilavy DB, et al. Intermittent intravenous cyclophosphamide for lupus nephritis. J Pediatr 1989;114:1055-60.
3. Pando JA, Gourley MF, Boumpas DT, Austin HA III, Balow JE, Klippel JH. Rates of renal remission and relapse in patients with lupus nephritis treated with bolus cyclophosphamide (abstract). Arthritis Rheum 1994; 37(suppl 9):S179.
4. Finley RS. Nausea and vomiting. In: Koda-Kimble MA, Young LY, eds. Applied therapeutics. The clinical use of drugs. 5th ed. Vancouver, WA: Applied Therapeutics, 1992:6-1-13.
5. Cooke CE, Mehra IV. Oral ondansetron for preventing nausea and vomiting. Am J Hosp Pharm 1994;51:762-71.
6. Forrest A, Amantea MA, Pucino F, Yarboro C, Klippel JH. Population pharmacodynamics (PDs) of intravenous and oral ondansetron in patients with systemic lupus erythematosus (SLE). Annual Scientific Meeting of the American Society of Clinical Pharmacology and Therapeutics. New Orleans, March 31-April 2, 1994.
7. Amantea MA, Yarboro C, Forrest A, Pucino F, Klippel JH. Population pharmacokinetics (PKs) of intravenous and oral ondansetron in patients with systemic lupus erythematosus (SLE). Annual Scientific Meeting of the American Society of Clinical Pharmacology and Therapeutics. New Orleans, March 31-April 2, 1994.
8. Smith DB, Newlands ES, Spruyt OS, Begent RH, Austin GJ, Mellar B, et al. Ondansetron (GR38032F) + dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy. Br J Cancer 1990;61:323-4.
9. Cunningham D, Turner A, Hawthorn J, Rosin RD. Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis (letter). Lancet 1989;1:1323.
10. Marschner NW, Adler M, Nagel GA, Christmann D, Fenzl E, Upadhyaya B. Double-blind randomized trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer 1991; 27:1137-40.
11. Rosso R, Campora E, Cetto G, Fosser V, Marangolo M, Oliva C. Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide-induced emesis. Anticancer Res 1991;11:937-9.
12. 1994 Physicians' desk reference. 48th ed. Montvale, NJ: Medical Economics Data Production, 1994:797.
13. Beck T, Cicciola AA, Jones SE, Harvey WH, Tchekmedyian NS, Chang A, et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 1993;118:407-13.
14. Garrett H, ed. 1994 Red book. Montvale, NJ: Medical Economics Data Production, 1993.
15. 3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Am J Clin Oncol 1994;17:137-46.